Here’s why GSK and Haleon shares have tanked this week

Shares in both GSK and its spin-off Haleon have plummeted this week. Edward Sheldon looks at what’s going on and whether this is a buying opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s fair to say it’s been a bad week for both GSK (LSE: GSK) and Haleon (LSE: HL) shares. After starting the week at 1,667p, GSK has fallen to around 1,430p. Spin-off Haleon, meanwhile, has fallen to around 266p after beginning the week at 308p.

So, what’s going on with these two UK stocks? And has the recent share price weakness provided a buying opportunity for me?

Why GSK and Haleon are down this week

The reason the two companies have seen their share prices fall this week is that investors are concerned about US litigation related to Zantac, a heartburn drug. Zantac – which was originally marketed by a forerunner of GSK – was withdrawn from shelves in 2019 after being linked to cancer.

According to Credit Suisse, more than 2,000 lawsuits have been filed in the US (against a number of healthcare companies that sold the drug), with the first trial beginning later this month. And analysts at Morgan Stanley say the total damages could be as high as $40bn.

I’ll point out that this is not exactly new news. The issue has been rumbling on in the background for several years now and in its recent prospectus, Haleon highlighted the risk of potential lawsuits. However, the litigation has received more media attention lately, and as a result, investors have panicked.

I think the panic … really comes down to market psychology as opposed to having learned anything new,” wrote Barclays analyst Emily Field in an email earlier this week.

Zantac statements

It’s worth noting that both GSK and Haleon have released statements regarding Zantac litigation today.

It its statement, GSK said:

  • Based on investigations and experiments, GSK, the US Food & Drug Administration (FDA), and the European Medicines Agency all independently concluded that there’s no evidence of a causal association between Zantac and the development of cancer.
  • Plaintiff litigation is inconsistent with the scientific consensus and the company will vigorously defend all claims.

Meanwhile, in its statement, Haleon said:

  • It’s not aware of any material developments in relation to the Zantac litigation since the Haleon prospectus was issued in June.
  • It’s not a party to any of the Zantac claims.

These statements suggest to me that both companies believe that they’re in the clear here.

Is this a buying opportunity?

After the recent share price falls, both GSK and Haleon trade at relatively low valuations. GSK trades at around 11 times this year’s forecast earnings while Haleon trades at around 15. So, there could be some value on offer here. However, given the uncertainty over the litigation, I’m not convinced the risk/reward is so attractive right now.

Looking past the potential litigation, there are other issues that concern me. GSK has lost its consumer health business, which was the area of the business I liked the most due to its stability. Without this, revenues could be more volatile.

Meanwhile, Haleon has a huge debt pile, which is an issue in a rising-interest-rate environment. Additionally, GSK and Pfizer plan to sell their Haleon shares when the lock-up period ends in November. This could put pressure on the share price.

All things considered, I think the best move, for me personally, is to leave these two stocks alone for now and focus on better, safer opportunities.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc and Haleon plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »